Kornimate/medical-research-clean huggingface dataset:
magnetic resonance imaging of the coronary vessel wall

Conditions: Coronary Artery Disease

Summary: despite advances in prevention and treatment, clinical manifestations of atherosclerosis (e.g. myocardial infarction, stroke) remain the largest cause of mortality in the western world. the occurrence of acute ischemic syndromes, including unstable angina and myocardial infarction, is highly associated with atherosclerotic plaque morphology. magnetic resonance (mr) imaging is able to noninvasively depict the lumen of coronary arteries without the need for ionizing radiation. in addition, mr imaging is able to generate soft-tissue contrast unlike any other imaging modality. it has been shown in the aorta and carotid artery that mr imaging is able to identify different atherosclerotic plaque components in vivo. similar mr imaging techniques are becoming available to visualize the coronary arterial wall and preliminary studies have shown the feasibility of mr coronary vessel wall imaging in humans. the overall aim of the current study is to identify in vivo mr coronary vessel wall and plaque features that are associated with acute coronary syndromes. this study is divided into 2 substudies: 1. detection of atherosclerosis in the coronary vessel wall with contrast-enhanced mr imaging in patients with coronary artery disease and age-matched healthy volunteers. 2. characterization of coronary vessel wall plaque morphology in patients with stable and unstable angina: validation of mri with the current standard of reference intravascular ultrasound (ivus).


Eligibility criteria:
inclusion criteria: * patients with (un)stable angina or non-st-elevated myocardial infarction * patients are scheduled for, or recently had x-ray coronary angiography * healthy volunteers, no clinical history of coronary artery disease(control group for substudy 1) * patients with non-ischemic heart disease, scheduled for x-ray coronary angiography (control group for substudy 2) * informed consent exclusion criteria: * severe arrhythmia * hemodynamic unstable patients * contra-indications for mri

Keywords: coronary atherosclerosis magnetic resonance imaging vulnerable plaque
development of sleep intervention for parent and child

Conditions: Behavioral Insomnia of Childhood

Summary: this study aims to develop and test the intervention program to help manage parental thoughts in parents with child sleep problems.

pediatric sleep problems are common and persistent, which result in negative outcomes without appropriate intervention. behavioral sleep interventions (bsi) are evidence-based sleep training methods for improving pediatric sleep. however, parental factors (e.g., parental dysfunctional beliefs about child sleep) can interfere with the implementation of bsi. for example, being too worried or having misperceptions about infant sleep may interfere with the parent's ability to successfully and persistently implement bsis. therefore, parental thoughts and beliefs should be considered as an important target in the context of pediatric sleep interventions. this study aims to develop a cognitive intervention that identifies and targets parental misperceptions about child's sleep, and test the efficacy of the intervention through a randomized controlled trial.

Eligibility criteria:
inclusion criteria: * child's primary nighttime caregiver (mothers or fathers) of full-term, healthy, singleton, 6 to 24 months old * caregiver participants aged between 19 to 65 years * the caregiver who is a native speaker of korean (a person who is able to listen, speak, and write in korean, and does not have any difficulties in understanding the korean language) * residents of south korea * sleep arrangements without restriction for using an auto-videosomnography device: (1) parent-child sleep separately (one should not change the sleep arrangement only for the participation in the study); (2) if parents and child share a bed, the child's own space should be large enough for the videosomnography camera to capture child body solely. * be available on devices with the camera (e.g., tablets, personal computers) for the online intervention/session exclusion criteria: * child's gestational age before 37 weeks or after 42 weeks * children with developmental disability * caregiver participant (or partner) who is currently working the night shift or night duty * caregiver participant who has a history of sleep disorders besides insomnia * caregiver participant who has lifetime bipolar disorder, schizophrenia spectrum, and other psychotic disorders, alcohol, caffeine, or other substance substance-related disorders, neurocognitive disorders, thyroid-related disorders, or epilepsy * caregiver participant who is currently experiencing a major depressive disorder, panic disorder (only if ≥ 4 nocturnal panic attacks in the past month), or post-traumatic stress-related problems * caregiver participant who is using medications or substances that directly affect sleep * caregiver participant who is currently getting cognitive behavioral therapy for insomnia (cbti) * pregnant women

Keywords: pediatric sleep problems sleep intervention cognitive behavioral therapy (cbt)
inhaled nitric oxide in prevention/treatment of ischemia-reperfusion lung injury related to lung transplantation

Conditions: Ischemia-Reperfusion Injury

Summary: the purpose of this study is to evaluate the effects of inhaled nitric oxide on both short-term physiology as well as on the development of ischemia-reperfusion lung injury (irli) in the immediate post transplant period. the specific hypothesis is that inhaled no post lung transplantation will improve gas exchange/hemodynamic and thus reduce the development of post transplant irli.

the objective is to determine the role of inhaled no in the prevention/treatment of irli in lung transplant patients. the plan is to accomplish this objective in 2 phases: phase 1 - patients immediately post transplant will have a variety of physiologic measurements performed while breathing 0, 10, and 20 ppm inhaled no. for the next 24 hours they will be kept on a mixture providing the best oxygen delivery and pulmonary artery pressure. our specific aims in this phase are to characterize physiologic responses to inhaled no and determine the incidence of irli in these patients over 24 hours. phase 2 - patients immediately post transplant will be randomized to either ino or placebo gas and followed for 24 hours. our specific aim in this phase is to compare the rate of development of irli in the two groups.

Eligibility criteria:
inclusion criteria: * patients undergoing lung transplantation exclusion criteria: * participation in other experimental protocols

Keywords: ischemia-reperfusion lung injury irli
correlation of muscle ultrasound measures (2d and 3d) with biphotonic x-ray absorptiometry in oldest old patients.

Conditions: Assessment, Self; Muscle Atrophy; Ultrasound Therapy; Complications; Aging

Summary: the sarcopenia diagnosis is based on the muscle mass and on impaired physical performance. the emerging field of ultrasound assessment of muscle mass in older patients is based on 2d parameters with prediction equations for muscle mass. for the moment, validation of prediction equations in older adults with varying function and health is lacking. the study aims to evaluate correlation of muscle mass between 3d muscle mass measurement and dxa, in order to dispense with the prediction equation.

older patients who agree to participate to the study will undergo 3d ultrasound muscle mass measurement, 2d panoramic mode muscle mass measurement and biphotonic x-ray absorptiometry assessment. correlation analysis will be done with the different measurement.

Eligibility criteria:
inclusion criteria: * patients over 75 years old * osteoporosis diagnosis confirmed by dual-energy x-ray absorptiometry exclusion criteria: * neurocognitive disorders preventing the expression of informed consent * patients who cannot undergo an examination in a static position * lack of a measurement site (muscle resection or amputation) * any state of dehydration or water inflation * patient with legal protection measure
comparison of morbidity after laparoscopic cholecystectomy for acutely inflamed gall bladder with and without drain

Conditions: Acute Cholecystitis; Pain; Morbidity, Multiple; Surgery; Drain Site Complication

Summary: the purpose of this study was to compare the frequency of pain and mean hospital stay in patients with and without drain insertion, following laparoscopic cholecystectomy for acutely inflamed gallbladder.

most hospitals in pakistan still do not have a policy of early laparoscopic cholecystectomy in acutely inflamed gallbladder, partly because of feared higher conversion rates to open procedure and presumed increased risk of complications. there are fewer local studies to elaborate the role of drain after laparoscopic cholecystectomy for acutely inflamed gallbladder. this study was conducted to analyze the role of routine use of drains after laparoscopic cholecystectomy for acutely inflamed gallbladder. does it offer any advantage in detecting bile leak or bleeding. also to prove that placing drains prolongs the hospital stay and increases postoperative pain in comparison to patients in whom drain is not placed. after being informed about the study and the potential risks, all patients giving written informed consent, underwent laparoscopic cholecystectomy using conventional 4 port method. patients were divided in two groups by lottery method. group a - no drain group and group b - drain group. post operatively parameters of pain and total hospital stay were assessed and analysed.

Eligibility criteria:
inclusion criteria: * all the patients of either sex with ages between 20 - 80 years, diagnosed with acutely inflamed gallbladder, undergoing laparoscopic cholecystectomy were included in the study exclusion criteria: * all patients having concurrent operations on other organs, or with history of previous upper abdominal surgery, or with immunodeficiency states because of liver or renal transplantation or already diagnosed with hiv infection, or surgeries requiring open conversions, or surgeries in which there was hollow visceral organ injury, or patient requiring common bile duct (cbd) exploration or patients having any bleeding disorder, or surgeries where there is doubt of cystic duct stump or cbd injury, were excluded from the study

Keywords: pain hospital stay drain insertion laparoscopic cholecystectomy acutely inflammed gall bladder
relative bioavailability study to assess an lc350189 tablet compared to an lc350189 capsule in healthy adults

Conditions: Gout; Hyperuricemia

Summary: this is an open-label, randomized, crossover, single dose study. two single doses of lc350189(tablet or capsule formulations) will be administered with a washout period of at least 4-day between the doses to investigate the relative bioavailability of lc350189 after administration via tablet formulation compared with capsule formulation and to evaluate basic systemic pharmacokinetic parameters of the tablet formulation compared to the capsule formulation of lc350189.


Eligibility criteria:
inclusion criteria: * the subject is male or female 18 to 50 years of age, inclusive. * the subject has a body mass index 18 to 32 kg/m2, inclusive, at screening. * the subject is judged by the investigator to be in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12 lead electrocardiogram (ecg) results, and physical examination findings at screening. * the subject agrees to comply with all protocol requirements. * the subject is able to provide written informed consent. exclusion criteria: * the subject has a medical history with any issues affecting absorption or metabolism, as judged by the investigator. * the subject has a positive test result for hepatitis b surface antigen, hepatitis c virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at screening. * the subject has a positive test result for sars-cov-2 at screening. * the subject has used any prescription (excluding hormonal birth control and hormone replacement therapy) or over the counter medications (except paracetamol \[up to 2 g per day\]), including herbal or nutritional supplements, within 14 days before the first dose of study drug or throughout the study. * the subject has consumed grapefruit or grapefruit juice, seville orange or seville orange containing products (eg, marmalade), or caffeine- or xanthine containing products within 48 hours before the first dose of study drug or throughout the study. * the subject is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug. * the subject has a history of alcohol abuse or drug addiction within the last year or excessive alcohol consumption (regular alcohol intake \>21 units per week for male subjects and \>14 units of alcohol per week for female subjects) (1 unit is equal to approximately ½ pint \[200 ml\] of beer, 1 small glass \[100 ml\] of wine, or 1 measure \[25 ml\] of spirits). * the subject has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at screening or before the first dose of study drug.

Keywords: bioavailability relative
safety and efficacy of ranolazine for the treatment of amyotrophic lateral sclerosis

Conditions: ALS

Summary: the purpose of this research study is to evaluate the safety and effectiveness of ranolazine, and how well it is tolerated in patients with amyotrophic lateral sclerosis (als). ranolazine is an fda approved drug that is used for decreasing chest pain.

amyotrophic lateral sclerosis (als) is a progressive debilitating and fatal neurodegenerative disease involving the motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord with 5,000 newly diagnosed patients per year in the usa. there is a pressing need for additional therapies, as the only two fda-approved drugs for als, riluzole and edaravone, showed prolongation of median survival of only two to three months and only a modest benefit in daily functioning, respectively. the ability to identify fda approved drugs which can be repurposed to als, and which may slow disease progression, alleviate symptoms, or prolong survival will have an immediate positive impact of the lives of patients with als and their family members. hypothesis: ranolazine, an fda approved drug for angina which inhibits the late na+ current and intracellular ca2+ accumulation may be neuroprotective in als by reducing neuronal hyperexcitability, may slow disease progression and reduce cramp frequency.

Eligibility criteria:
inclusion criteria: * patients with clinically definite, probable, laboratory supported probable, or possible als per revised el escorial criteria * cramp frequency greater than 4 cramps per week during 2 week run in * als functional rating scale-revised (alsfrs-r) score of greater than 24 * able to lie on back for study procedures exclusion criteria: * tracheostomy invasive ventilation, or use of non-invasive ventilation greater than 12 hours per day * pregnant or lactating * participation in a prior experimental drug trial less than 30 days prior to screening * patients taking ranolazine * patients taking medications which are contraindicated for use with ranolazine such as strong cyp3 inhibitors (ketoconazole, clarithromycin, nelfinavir), and cyp3 inducers (rifampin, phenobarbital) * patients with clinically significant medical comorbidities (hepatic, renal, cardiac, etc) * patients with baseline qt interval prolongation on electrocardiography (ecg) * patients pre-disposed to secondary qt prolongation for other health conditions like family history of congenital long qt syndrome, heart failure, bradycardia, or cardiomyopathies
study of metronidazole and doxycycline to treat oral lichen planus and to compare their efficacy with each other

Conditions: Oral Lichen Planus

Summary: oral lichen planus (olp) is a chronic inflammatory disorder which causes local irritation,discomfort and subsequent poor dentition and discomfort in eating . various treatments have been suggested for olp but their results are unsatisfactory .despite the fact that steroids have been the main therapeutic choice for many years,some researches have been done regarding the efficacy of other medication such as metronidazole and doxycycline.the purpose of this study is to determine whether metronidazole and doxycycline are effective in the treatment of oral lichen planus and to compare their efficacy with each other.


Eligibility criteria:
inclusion criteria: * a biopsy-proven untreated olp of every type with no symptom. exclusion criteria: * pregnancy, presence of dysplasia in lesions,unilateral lesion suspected lichenoid reaction,history of drinking alcohol in at least 1 month prior to the study, smoking, systemic disease, use of systemic medications and hypersensitivity to the metronidazole and doxycycline.

Keywords: oral lichen planus metronidazole doxycycline
preimplantation genetic diagnosis using blastocyst biopsy and array cgh

Conditions: Infertility; Recurrent Pregnancy Loss

Summary: the investigators propose to perform a clinical randomized trial to evaluate the effect of single embryo (blastocyst) transfer (set) with array cgh for the evaluation of the complete chromosome complement of the blastocyst in comparison to standard art methods in which one or more embryo are replaced. patients will be randomized into two groups: * control group: patients will have up to two embryos replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. if patients in the control group do not have a pregnancy to term from that fresh cycle, they will be offered free pgd either for the frozen embryos of that cycle or for the next cycle (up to the center and patient). data from that pgd is not part of the study. * test group: patients will have grade a,b or c blastocysts hatched on day 5, biopsied on day 5, analyzed by array cgh, and a single euploid embryo transferred on day 6. any morulas developing to grade a,b or c blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.

patients will be randomized after fertilization, and will be dropped from the study if they produce 3 or less blastocysts on day 5. the primary efficacy endpoint of comparing the study group with the control will be (i) implantation rates and (ii) multiple pregnancies (twin or higher order) comparing the first transfer. the study may be extended to evaluate secondary efficacy endpoints which will be miscarriage rate and take home baby rates comparing the two groups.

Eligibility criteria:
inclusion criteria: * maternal age 33 to 42 years old (included) exclusion criteria: * mesa and tese patients * at least one partner carrier of a chromosomal or genetic disease * abnormal ovarian reserve, defined as fsh of \>10 iu/l on day 2-4 of the cycle and amh \< 1ng /ml (if only one of the two parameters altered then patients is acceptable). * egg donor cycle (sperm donor is acceptable) exclusion criteria during stimulation: * less than eight antral follicles on day 2-4 of cycle exclusion criteria on day 5 post retrieval: * patients will be excluded if they produce less than 3 grade a,b or c blastocysts by day 5.

Keywords: infertility, recurrent pregnancy loss, miscarriage
immunotherapy administered under the tongue to treat dust mite allergy

Conditions: Asthma

Summary: this study will investigate sublingual immunotherapy (slit), a treatment involving antigens placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing substances. specifically, this study will determine the effectiveness of slit at two different dosing regimens for patients with intermittent mild asthma caused by dust mites.

asthma is a serious lung condition that is the leading cause of long-term illness in children. many common household substances can trigger or worsen an asthma attack. it is important for people to reduce household allergens and learn effective treatments for specific types of asthma. inhaled short-acting beta agonist such as albuterol is the standard treatment for mild, intermittent asthma. however, recent studies have shown that adding allergen-specific immunotherapy to your current asthma therapy can help to control asthma symptoms. this study will determine the safety and effectiveness of slit in two different dosing regimens in treating patients with house dust mite-induced allergic rhinitis/mild intermittent asthma. participants will be randomly assigned to receive low dose slit, high dose slit, or placebo for at least 12 months. house dsut mite-induced allergy skin tests will be performed at study entry, at selected timepoints throughout the study, and at the end of the study. the tests will determine whether slit creates an immune tolerance state as well as whether slit acts via local or systemic immunological systems.

Eligibility criteria:
inclusion criteria: * house dust mite-induced allergic rhinitis/mild intermittent asthma exclusion criteria: * use of previous allergy immunotherapy for house dust mite asthma * pregnancy or breastfeeding

Keywords: breathing allergy mites, house dust
interferon alpha therapy for cervical cini and hpv infection

Conditions: Cervical Dysplasia; HPV Infection

Summary: mongolia is a traditionally nomadic and population is scarce in rural areas. thus, the medical care service is not sufficient. in 2000, mongolian government has developed and implemented the millennium project in cooperation with who. during the years pap smear analysis of implemented in all rural areas and clinicians, lab technicians have been taught for the cervical cancer screening. however, the project has finished in 2015 and the rural and district hospitals has lost the trained professionals. still the cervical cancer is in second place after liver cancer in women. the purpose of the study is to identify the type of hpv genotype and to treat the hpv infection by local interferon α2b. materials and methods: hpv positive patients will be enrolled to the study. hpv genotype will be determined by the pcr in laboratory. pap smear will be taken and staged by the cin. pathological tissue will be taken under colposcopy with acetic acid test. follow up visit will be done on 10th, 30th days of the treatment. at the end of 90th days of treatment, pap and histology test will be repeated and cin regression or viral eradication will be evaluated.

the purpose of the study is to evaluate the efficacy of interferon treatment for hpv infection shedding and early cin change. women aging from 20-40 years will be enrolled in the study. the treatment will be held in two arms. one arm will be administered only vaginal gel interferon treatment. the other arm will receive both vaginal gel interferon and rectal suppositories with interferon dosing 3,000,000 iu. in the beginning of the study all patient will have cervical pap smear and hpv typing. hpv testing will be done using real time pcr method to determine the subtype of hpv (16,18,31,33,35,39,45,51,52,56,59,68). at the beginning and at the end of the study all patient will have histology test. histology test will be done giemsa staining and evaluated by who 2014 classification of cervical histology including cini, cinii, ciniii, cervical cancer in situ and further. pap smear will be evaluated by bethesda classification. immunohistology staining will be done on the cervical tissue using anti-cd3 and anti-cd19 to evaluate the b cell invasion into the cervix.

Eligibility criteria:
inclusion criteria: * pap smear lsil * hpv infection positive * no anti-viral treatment in 2 weeks before treatment exclusion criteria: * no consent has obtained * anti-viral treatment in 2 weeks * breastfeeding or pregnant

Keywords: cin i, hpv infection